Nitroglycerin: Usage and Care. Nitroglycerin has an important clinical status and is widely used in the treatment of a wide range of diseases, but correct usage and awareness of care are essential to ensure treatment effectiveness and patient safety.
Use (i) Oral administration is a common method of delivery for most nitromazole-type substances, such as americium or ammonium. In the case of americium, for example, the intestinal amiba disease is treated at one time – 0.4 – 0.6 g, three times a day, seven days of treatment. In the treatment of trichomoniasis, one day, four times, seven days. In treatment of anaerobic infections for nitro, 1 g a day, 1 dose a day, double the first dose. Oral drugs are best taken after meals, which reduces the irritation of the gastrointestinal tract and increases patient tolerance. (ii) In the case of some serious infections, such as pelvic anaerobic infections, an intravenous drip may be used. For example, anaerobic infections are used when mitazine vein drops are injected for the first time at weight of 15 mg/kg (70kg adult 1g) and maintenance at weight of 7.5 mg/kg per 6 – 8 hour vein drops. In the course of intravenous dripping, attention should be paid to the dilution concentration and drip speed of the drug, which generally needs to be diluted with a special infusion solvent, and to ensure that dripping is completed within a specified time frame.
II. Usage (i) Adult use (i) Different diseases and different types of nitromazole-type drugs, with differences in use. In the treatment of anaerobic infections such as bacterial vaginal infections, oral doses of mitazole are often 0.2 – 0.4 g/day. In the case of the treatment of pseudo-film enteritis caused by the difficult scortia, the oral dose of mitraz can be increased to 0.4 g, 3 – 4 times a day. For some complex pelvic infections, combined use of nitrazine and other antibiotics may be required, with a dose of nitrazine venomic droplets of 500 mg per 8 hour. (ii) Child use. Children need to be particularly careful about the use of nitromazole. The dose is usually calculated on the basis of body weight, i.e., americium, at 35 – 50 mg/kg body weight per day, in three oral sessions and 10 days as a treatment. However, for the specific use of children, doctors need to take into account a combination of factors, such as condition, age and weight, especially for newborns and infants, whose liver and kidney function is not fully developed and which is subject to strict dose control.
III. NOTES
(i) Gastrointestinal reaction. The most common adverse reaction of nitro-mitropharmaceuticals is gastrointestinal irritation. Patients may suffer from conditions such as nausea, vomiting, appetite and abdominal strangulation. In the course of drug use, if these symptoms are light, an attempt can be made to mitigate them by adjusting diets, such as eating less and choosing digestible foods. If symptoms seriously affect food and life, the doctor should be informed in a timely manner whether there is a need to adjust the medication programme.
(ii) Symptoms of the nervous system. Some patients may experience adverse reactions to the nervous system such as headaches, dizziness, body numbness, hysteria, etc. In particular, large doses or long-term use are more likely to occur. In the event of these symptoms, the medication is stopped and the corresponding neurological system is examined to avoid more serious damage.
(iii) Allergic reactions, although relatively low, may occur in patients with rashes, itchings, damps, etc. Patients with a sensitive history must inform the doctor before they can be used so that he can choose a more appropriate treatment. In the case of allergies in the course of drug use, the use should be discontinued and allergies treated.
(iv) Prohibition of drinking during the use of nitromium-type drugs, which inhibit alcohol metabolism, result in accumulation in the body and cause a double-sulphine reaction. Patients may have symptoms of facial redness, headache, dizziness, abdominal pain, nausea, vomiting, agitation, increased heart rate, reduced blood pressure and even life-threatening conditions. Drinking should also normally be avoided within 1-2 weeks of a stoppage to ensure safety.
(v) Special population groups. Pregnant and lactating women should be careful to use nitromite-type drugs, especially in the early stages of pregnancy, which may have adverse effects on the foetus. If they have to be used, the advantages and disadvantages need to be weighed under the guidance of a doctor. Older persons are likely to experience varying degrees of reduction in liver and kidney function, and appropriate dose adjustments are also required to monitor the adverse effects closely.
In sum, nitromium-type drugs play an important role in the treatment of a wide range of infectious diseases, but the right amount of use and strict compliance with care are key to safe and effective use, requiring high priority by both patients and health-care providers.
